LIANBIO-ADR (LIAN) Stock Price & Overview
NASDAQ:LIAN • US53000N1081
Current stock price
The current stock price of LIAN is 0.319 USD. Today LIAN is down by -8.28%. In the past month the price decreased by -93.31%. In the past year, price decreased by -80.9%.
LIAN Key Statistics
- Market Cap
- 34.472M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
LIAN Stock Performance
LIAN Stock Chart
LIAN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LIAN. When comparing the yearly performance of all stocks, LIAN is a bad performer in the overall market: 99.75% of all stocks are doing better.
LIAN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LIAN. LIAN has a great financial health rating, but its profitability evaluates not so good.
LIAN Earnings
LIAN Forecast & Estimates
6 analysts have analysed LIAN and the average price target is 3.98 USD. This implies a price increase of 1147.02% is expected in the next year compared to the current price of 0.319.
For the next year, analysts expect an EPS growth of 16% and a revenue growth -100% for LIAN
LIAN Groups
Sector & Classification
LIAN Financial Highlights
Over the last trailing twelve months LIAN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 28.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.47% | ||
| ROE | -43.49% | ||
| Debt/Equity | 0 |
LIAN Ownership
LIAN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LIAN
Company Profile
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. The company has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Company Info
IPO: 2021-10-28
LIANBIO-ADR
103 Carnegie Center Drive, Suite 309, Suite 215
Princeton NEW JERSEY US
Employees: 163
Phone: 16094862308
LIANBIO-ADR / LIAN FAQ
What does LIAN do?
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. The company has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
What is the current price of LIAN stock?
The current stock price of LIAN is 0.319 USD. The price decreased by -8.28% in the last trading session.
What is the dividend status of LIANBIO-ADR?
LIAN does not pay a dividend.
How is the ChartMill rating for LIANBIO-ADR?
LIAN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When is the next dividend date for LIANBIO-ADR (LIAN)?
The next ex-dividend date for LIANBIO-ADR (LIAN) is March 15, 2024.
What is LIANBIO-ADR worth?
LIANBIO-ADR (LIAN) has a market capitalization of 34.47M USD. This makes LIAN a Nano Cap stock.
What is the next earnings date for LIAN stock?
LIANBIO-ADR (LIAN) will report earnings on 2024-05-09, after the market close.